CervoMed Inc. (NASDAQ: CRVO) announced new analyses from its Phase 2b RewinD-LB clinical trial of neflamapimod for dementia with Lewy bodies (DLB) treatment. The data was presented at the AD/PD 2026 Conference in Copenhagen, Denmark.

The analyses show that DLB patients with lower plasma pTau181 levels experienced greater clinical benefit from neflamapimod treatment. These patients are considered to have an earlier stage of disease and absence of Alzheimer's disease co-pathology.

In the trial, participants with plasma pTau181 levels below 21 pg/mL showed the strongest treatment response. At this threshold, the company estimates 80% to 90% of patients lack Alzheimer's disease co-pathology. CervoMed plans to use this 21 pg/mL cutoff as an enrichment criterion for its planned Phase 3 trial.

The RewinD-LB trial included 159 participants across 43 sites in the United States, United Kingdom, and Netherlands. The study was primarily funded by a $21.3 million grant from the National Institutes of Health's National Institute on Aging.

New pharmacokinetic analyses revealed that a trough plasma drug concentration of 4 ng/mL was the threshold for therapeutic activity. In the trial, 75% of participants receiving DP Batch B capsules achieved this target compared to 50% receiving DP Batch A capsules.

"The clinical and biomarker activity that we are seeing with neflamapimod provides a strong indication that we are successfully targeting the underlying cause of disease in the basal forebrain," said Dr. John Alam, Chief Executive Officer of CervoMed.

CervoMed plans to initiate a Phase 3 trial in the second half of 2026, subject to available funding. The trial will enrich for patients without Alzheimer's disease co-pathology using the plasma pTau181 biomarker threshold.